ANKRD13C Inhibitors
ANKRD13C inhibitors constitute a diverse array of chemical compounds that indirectly suppress the functional activity of ANKRD13C by targeting various cellular pathways and processes with which ANKRD13C is intricately linked. Rapamycin, through its inhibition of the mTOR pathway, an influential regulator of protein degradation, may impede the endocytic sorting function of ANKRD13C by altering the cellular milieu in which ANKRD13C operates. Similarly, actin cytoskeleton dynamics, whichis a fundamental aspect of vesicular trafficking, is targeted by compounds such as Wiskostatin, NSC 23766, Cytochalasin D, Latrunculin A, and GW 627368X which all disrupt the architecture of the cytoskeleton, thereby indirectly leading to a reduction in ANKRD13C-mediated vesicle formation and movement.
Further inhibitors, such as PD 98059, Mdivi-1, Brefeldin A, Pitstop 2, SecinH3, and DBeQ, each affect ANKRD13C by modulating distinct aspects of the endocytic and exocytic pathways. PD 98059 impacts the MAPK/ERK pathway, which may affect the ubiquitination roles of ANKRD13C and its associated receptor internalization. Mdivi-1 and Pitstop 2 specifically target clathrin-mediated endocytosis, a pathway crucial for ANKRD13C's role in sorting ubiquitinated receptors, by inhibiting dynamin and adaptor protein interactions, respectively. Brefeldin A's disruption of the Golgi apparatus inhibits vesicular transport processes that are essential for ANKRD13C's trafficking functions. SecinH3's inhibition of cytohesin affects ARF6, impacting actin remodeling and endocytosis, which are processes fundamental to ANKRD13C's role. Lastly, DBeQ disrupts exocyst complex assembly, which is pivotal for vesicle tethering, a process in which ANKRD13C could be implicated. Collectively, these inhibitors, through their targeted mechanisms, contribute to a comprehensive approach to reducing ANKRD13C's functional activity in cellular trafficking pathways.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin binds to FKBP12 and inhibits mTOR, which is part of the pathway that regulates protein degradation. ANKRD13C is implicated in endosomal sorting and trafficking, processes that can be affected by mTOR inhibition, leading to diminished ANKRD13C-mediated endocytic sorting. | ||||||
Wiskostatin | 253449-04-6 | sc-204399 sc-204399A sc-204399B sc-204399C | 1 mg 5 mg 25 mg 50 mg | $49.00 $124.00 $441.00 $828.00 | 4 | |
Wiskostatin inhibits N-WASP which is an effector of the CDC42 GTPase involved in actin polymerization. By inhibiting actin dynamics, wiskostatin can indirectly diminish ANKRD13C's role in vesicle trafficking, as actin remodeling is crucial for this process. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is a MEK inhibitor that disrupts the MAPK/ERK pathway. ANKRD13C, through its ubiquitination roles, may be impacted by the altered signaling, leading to decreased functional activity in processes such as receptor internalization. | ||||||
Mdivi-1 | 338967-87-6 | sc-215291 sc-215291B sc-215291A sc-215291C | 5 mg 10 mg 25 mg 50 mg | $67.00 $126.00 $251.00 $465.00 | 13 | |
Mdivi-1 inhibits dynamin, a GTPase essential for clathrin-mediated endocytosis. This inhibition can diminish ANKRD13C function by impairing the recycling of receptors ANKRD13C associates with during endocytosis. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A disrupts the structure and function of the Golgi apparatus, inhibiting vesicular transport. This can indirectly decrease ANKRD13C activity by disrupting the trafficking pathways it is involved in. | ||||||
Cytochalasin D | 22144-77-0 | sc-201442 sc-201442A | 1 mg 5 mg | $165.00 $486.00 | 64 | |
Cytochalasin D binds to the barbed ends of actin filaments, preventing their elongation and thus inhibiting actin polymerization. This impedes vesicular traffic and can diminish ANKRD13C function related to vesicle formation and movement. | ||||||
Pitstop 2 | 1419320-73-2 | sc-507418 | 10 mg | $360.00 | ||
Pitstop 2 inhibits clathrin-mediated endocytosis by blocking the interaction of clathrin with adaptor proteins. This could lead to a decrease in ANKRD13C activity, as it is involved in sorting ubiquitinated receptors during endocytosis. | ||||||
Latrunculin A, Latrunculia magnifica | 76343-93-6 | sc-202691 sc-202691B | 100 µg 500 µg | $265.00 $815.00 | 36 | |
Latrunculin A binds to actin monomers and inhibits their polymerization. This disrupts cytoskeletal dynamics and can indirectly reduce ANKRD13C's role in the organization of endosomal sorting and trafficking. | ||||||
SecinH3 | 853625-60-2 | sc-203260 | 5 mg | $278.00 | 6 | |
SecinH3 is a cytohesin inhibitor that affects ARF6, a small GTPase involved in actin remodeling and endocytosis. Inhibition of this pathway can diminish ANKRD13C-mediated trafficking and sorting of proteins. | ||||||
DBeQ | 177355-84-9 | sc-499943 | 10 mg | $330.00 | 1 | |
DBeQ is an inhibitor of exocyst complex assembly, which plays a role in vesicle tethering during exocytosis. Inhibiting this process can diminish ANKRD13C's potential role in modulating vesicle trafficking. | ||||||